Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression

By A Mystery Man Writer

Parkinson's disease pathology is directly correlated to SIRT3 in human subjects and animal models: Implications for AAV.SIRT3-myc as a disease-modifying therapy - ScienceDirect

PDF) Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

Frontiers The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders

Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology, Molecular Neurodegeneration

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

New hopes for disease modification in Parkinson's Disease - ScienceDirect

Frontiers Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies

Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction

Peptide-based approaches to directly target alpha-synuclein in Parkinson's disease, Molecular Neurodegeneration

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

The Odyssey of Alpha-synuclein and Neuroinflammatory Mediators as Potential Candidates in the Aetiology of Parkinson's Disease

Parkinson's disease: Mechanisms, translational models and management strategies - ScienceDirect